For the evaluation of the secondary outcome and the detection of adverse events, data will be collected for each patient since informed consent is obtained in the Selection (Day -1 to 0), treatment period (days 1 to 5), follow-up period (Days 6 to 10) and in the late evaluation visit (day 30).